|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sher T, Dy GK and Adjei AA: Small cell
lung cancer. Mayo Clin Proc. 83:355–367. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Duffy MJ and O'Byrne K: Tissue and blood
biomarkers in lung cancer: A review. Adv Clin Chem. 86:1–21. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meza R, Meernik C, Jeon J and Cote ML:
Lung cancer incidence trends by gender, race and histology in the
United States, 1973–2010. PLoS One. 10:e01213232015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hellmann MD, Rizvi NA, Goldman JW,
Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ,
Juergens RA, et al: Nivolumab plus ipilimumab as first-line
treatment for advanced non-small-cell lung cancer (CheckMate 012):
Results of an open-label, phase 1, multicohort study. Lancet Oncol.
18:31–41. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Postow MA, Callahan MK and Wolchok JD:
Immune checkpoint blockade in cancer therapy. J Clin Oncol.
33:1974–1982. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li B, Cui Y, Diehn M and Li R: Development
and validation of an individualized immune prognostic signature in
early-stage nonsquamous non-small cell lung cancer. JAMA Oncol.
3:1529–1537. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Al-Shibli KI, Donnem T, Al-Saad S, Persson
M, Bremnes RM and Busund LT: Prognostic effect of epithelial and
stromal lymphocyte infiltration in non-small cell lung cancer. Clin
Cancer Res. 14:5220–5227. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nedergaard BS, Ladekarl M, Nyengaard JR
and Nielsen K: A comparative study of the cellular immune response
in patients with stage IB cervical squamous cell carcinoma. Low
numbers of several immune cell subtypes are strongly associated
with relapse of disease within 5 years. Gynecol Oncol. 108:106–111.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nielsen JS, Sahota RA, Milne K, Kost SE,
Nesslinger NJ, Watson PH and Nelson BH: CD20+ tumor -infiltrating
lymphocytes have an atypical CD27- memory phenotype and together
with CD8+ T cells promote favorable prognosis in ovarian cancer.
Clin Cancer Res. 18:3281–3292. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu J, Lichtenberg T, Hoadley KA, Poisson
LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee
AV, et al: An integrated TCGA pan-cancer clinical data resource to
drive high-quality survival outcome analytics. Cell.
173:400–416.e11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bhattacharya S, Andorf S, Gomes L, Dunn P,
Schaefer H, Pontius J, Berger P, Desborough V, Smith T, Campbell J,
et al: ImmPort: Disseminating data to the public for the future of
immunology. Immunol Res. 58:234–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Robinson MD, McCarthy DJ and Smyth GK:
EdgeR: A bioconductor package for differential expression analysis
of digital gene expression data. Bioinformatics. 26:139–140. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dennis G Jr, Sherman BT, Hosack DA, Yang
J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation,
visualization, and integrated discovery. Genome Biol. 4:P32003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu G, Wang LG, Han Y and He QY:
ClusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang da W, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: Paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wagenmakers EJ and Farrell S: AIC model
selection using Akaike weights. Psychon Bull Rev. 11:192–196. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu
JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis
of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heagerty PJ, Lumley T and Pepe MS:
Time-dependent ROC curves for censored survival data and a
diagnostic marker. Biometrics. 56:337–344. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chinese Association for Clinical
Oncologists, . Clinical practice guideline for stage IV primary
lung cancer in China(2020 version). Zhonghua Zhong Liu Za Zhi.
42:1–16. 2020.(In Chinese). PubMed/NCBI
|
|
25
|
Dong D, Ruuska SE, Levinthal DJ and Noy N:
Distinct roles for cellular retinoic acid-binding proteins I and II
in regulating signaling by retinoic acid. J Biol Chem.
274:23695–23698. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Favorskaya I, Kainov Y, Chemeris G,
Komelkov A, Zborovskaya I and Tchevkina E: Expression and clinical
significance of CRABP1 and CRABP2 in non-small cell lung cancer.
Tumour Biol. 35:10295–10300. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yurasov S, Wardemann H, Hammersen J,
Tsuiji M, Meffre E, Pascual V and Nussenzweig MC: Defective B cell
tolerance checkpoints in systemic lupus erythematosus. J Exp Med.
201:703–711. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pugh-Bernard AE, Silverman GJ, Cappione
AJ, Villano ME, Ryan DH, Insel RA and Sanz I: Regulation of
inherently autoreactive VH4-34 B cells in the maintenance of human
B cell tolerance. J Clin Invest. 108:1061–1070. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cappione A III, Anolik JH, Pugh-Bernard A,
Barnard J, Dutcher P, Silverman G and Sanz I: Germinal center
exclusion of autoreactive B cells is defective in human systemic
lupus erythematosus. J Clin Invest. 115:3205–3216. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Reubi JC, Laderach U, Waser B, Gebbers JO,
Robberecht P and Laissue JA: Vasoactive intestinal
peptide/pituitary adenylate cyclase-activating peptide receptor
subtypes in human tumors and their tissues of origin. Cancer Res.
60:3105–3112. 2000.PubMed/NCBI
|
|
31
|
Mlakar V, Strazisar M, Sok M and Glavac D:
Oligonucleotide DNA microarray profiling of lung adenocarcinoma
revealed significant downregulation and deletions of vasoactive
intestinal peptide receptor 1. Cancer Invest. 28:487–494. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gong X, Yi J, Carmon KS, Crumbley CA,
Xiong W, Thomas A, Fan X, Guo S, An Z, Chang JT and Liu QJ:
Aberrant RSPO3-LGR4 signaling in Keap1-deficient lung
adenocarcinomas promotes tumor aggressiveness. Oncogene.
34:4692–4701. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang J, Zhang Y, Dutta DJ, Argaw AT,
Bonnamain V, Seto J, Braun DA, Zameer A, Hayot F, Lòpez CB, et al:
Proapoptotic and antiapoptotic actions of Stat1 versus Stat3
underlie neuroprotective and immunoregulatory functions of IL-11. J
Immunol. 187:1129–1141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Trepicchio WL, Wang L, Bozza M and Dorner
AJ: IL-11 regulates macrophage effector function through the
inhibition of nuclear factor-kappaB. J Immunol. 159:5661–5670.
1997.PubMed/NCBI
|
|
35
|
Curti A, Ratta M, Corinti S, Girolomoni G,
Ricci F, Tazzari P, Siena M, Grande A, Fogli M, Tura S and Lemoli
RM: Interleukin-11 induces Th2 polarization of human CD4(+) T
cells. Blood. 97:2758–2763. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pastor MD, Nogal A, Molina-Pinelo S,
Quintanal-Villalonga Á, Meléndez R, Ferrer I, Romero-Romero B, De
Miguel MJ, López-Campos JL, Corral J, et al: IL-11 and CCL-1: Novel
protein diagnostic biomarkers of lung adenocarcinoma in
bronchoalveolar lavage fluid (BALF). J Thorac Oncol. 11:2183–2192.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yamazumi K, Nakayama T, Kusaba T, Wen CY,
Yoshizaki A, Yakata Y, Nagayasu T and Sekine I: Expression of
interleukin-11 and interleukin-11 receptor alpha in human
colorectal adenocarcinoma; immunohistochemical analyses and
correlation with clinicopathological factors. World J
Gastroenterol. 12:317–321. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hanavadi S, Martin TA, Watkins G, Mansel
RE and Jiang WG: Expression of interleukin 11 and its receptor and
their prognostic value in human breast cancer. Ann Surg Oncol.
13:802–808. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Morris R, Kershaw NJ and Babon JJ: The
molecular details of cytokine signaling via the JAK/STAT pathway.
Protein Sci. 27:1984–2009. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hanahan D and Coussens LM: Accessories to
the crime: Functions of cells recruited to the tumor
microenvironment. Cancer Cell. 21:309–322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
O'Shea JJ, Schwartz DM, Villarino AV,
Gadina M, McInnes IB and Laurence A: The JAK-STAT pathway: Impact
on human disease and therapeutic intervention. Annu Rev Med.
66:311–328. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Buzzelli JN, O'Connor L, Scurr M, Chung
Nien Chin S, Catubig A, Ng GZ, Oshima M, Oshima H, Giraud AS,
Sutton P, et al: Overexpression of IL-11 promotes premalignant
gastric epithelial hyperplasia in isolation from germline
gp130-JAK-STAT driver mutations. Am J Physiol Gastrointest Liver
Physiol. 316:G251–G262. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Stark GR and Darnell JE Jr: The JAK-STAT
pathway at twenty. Immunity. 36:503–514. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Inagaki-Ohara K, Kondo T, Ito M and
Yoshimura A: SOCS, inflammation, and cancer. JAKSTAT.
2:e240532013.PubMed/NCBI
|
|
45
|
Guo S, Contratto M, Miller G, Leichman L
and Wu J: Immunotherapy in pancreatic cancer: Unleash its potential
through novel combinations. World J Clin Oncol. 8:230–240. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ammirante M, Luo JL, Grivennikov S,
Nedospasov S and Karin M: B-cell-derived lymphotoxin promotes
castration-resistant prostate cancer. Nature. 464:302–305. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pinto R, Petriella D, Lacalamita R,
Montrone M, Catino A, Pizzutilo P, Botticella MA, Zito FA, Del Bene
G, Zonno A, et al: KRAS-driven lung adenocarcinoma and B cell
infiltration: Novel insights for immunotherapy. Cancers (Basel).
11(pii): E11452019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tsou P, Katayama H, Ostrin EJ and Hanash
SM: The emerging role of B cells in tumor immunity. Cancer Res.
76:5597–5601. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lee KE, Spata M, Bayne LJ, Buza EL, Durham
AC, Allman D, Vonderheide RH and Simon MC: Hif1a deletion reveals
pro-neoplastic function of B cells in pancreatic neoplasia. Cancer
Discov. 6:256–269. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Asare A, Kanaparthi S, Lim N, Phippard D,
Vincenti F, Friedewald J, Pavlakis M, Poggio E, Heeger P, Mannon R,
et al: B cell receptor genes associated with tolerance identify a
cohort of immunosuppressed patients with improved renal allograft
graft function. Am J Transplant. 17:2627–2639. 2017. View Article : Google Scholar : PubMed/NCBI
|
